CN202490227U - Novel viral inactivation leukocyte-reduction blood bag - Google Patents
Novel viral inactivation leukocyte-reduction blood bag Download PDFInfo
- Publication number
- CN202490227U CN202490227U CN2012201105469U CN201220110546U CN202490227U CN 202490227 U CN202490227 U CN 202490227U CN 2012201105469 U CN2012201105469 U CN 2012201105469U CN 201220110546 U CN201220110546 U CN 201220110546U CN 202490227 U CN202490227 U CN 202490227U
- Authority
- CN
- China
- Prior art keywords
- bag
- blood
- conduit
- filter
- methylene blue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 102
- 239000008280 blood Substances 0.000 title claims abstract description 101
- 230000002779 inactivation Effects 0.000 title abstract description 16
- 230000003612 virological effect Effects 0.000 title abstract description 9
- 210000002381 plasma Anatomy 0.000 claims abstract description 57
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229960000907 methylthioninium chloride Drugs 0.000 claims abstract description 37
- 238000003860 storage Methods 0.000 claims abstract description 15
- 239000003937 drug carrier Substances 0.000 claims abstract description 9
- 238000005286 illumination Methods 0.000 claims description 24
- 241000700605 Viruses Species 0.000 claims description 21
- 210000000265 leukocyte Anatomy 0.000 claims description 11
- 238000010521 absorption reaction Methods 0.000 claims description 10
- 230000009849 deactivation Effects 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 239000004743 Polypropylene Substances 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- -1 polypropylene Polymers 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 238000001914 filtration Methods 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 5
- 238000001179 sorption measurement Methods 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 4
- 230000010100 anticoagulation Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 description 12
- 239000000470 constituent Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Images
Abstract
The utility model relates to a novel viral inactivation leukocyte-reduction blood bag which comprises a closed blood taking needle and an anticoagulation whole blood bag, wherein the lower part of the anticoagulation whole blood bag is sequentially connected with a filter dripping hopper, a leukocyte-reduction filter and an after-filtration transfer bag by a conduit; the after-filtration transfer bag is sequentially connected with a blood plasma transfer bag, a blood plasma transfer lighting bag and a blood storage bag by a conduit; the conduit between the blood plasma transfer bag and the blood plasma transfer lighting bag is connected with a methylene blue releaser; the conduit between the blood plasma transfer lighting bag and the blood storage bag is connected with an adsorption filter; the leukocyte-reduction filter and the adsorption filter are respectively connected with a conduit with a switching clip in parallel through tee joints; and the methylene blue releaser is provided with a tubular shell, and drug carrier containing methylene blue solution is filled in the tubular shell. According to the novel viral inactivation leukocyte-reduction blood bag, the structure is reasonable, the operation and use are convenient, the methylene blue is released stably and reliably, the centrifugal separation is safe, and the centrifugal breakage to the blood bag is avoided, and the novel viral inactivation leukocyte-reduction blood bag is applicable to disposable blood collection, blood composition separation, viral inactivation and blood transfusion.
Description
Technical field
This utility model relates to a kind of disposable use medical disposable material, specifically a kind of new virus deactivation leukocyte depleted blood bag.
Background technology
We know that blood transfusion is a kind of requisite clinical treatment measure.But the same with other clinical treatment methods, blood transfusion (comprising blood constituent) also possibly cause the infectious disease that untoward reaction, complication and blood transfusion are relevant.Along with the component blood transfusion continuous advancement in technology, the safety of blood more and more receives publicity.And one of blood plasma blood constituent that to be viral level more influences transfusion safety without the normal transmitted virus of the blood plasma of viral inactivation treatment.According to statistics, the degree of danger of blood plasma infusion is that 7.5 untoward reaction can take place in 10000 units, and per 1000 patients that accept blood transfusion have 3.7 untoward reaction to take place.Although strengthened at present to blood donor's the selection and the detection of blood sample,, the spread disease danger of toxicity disease of blood transfusion still exists.So will safe blood or blood constituent be provided for clinical, must will strengthen examination and inactivation of virus combines, just can reach the purpose of transfusion safety.
The methylene blue photochemical method is considered to a kind of effective blood composition ablation method.China and European countries such as Germany, Switzerland have carried out deep research to method, effect and the safety of methylene blue blood-plasma virus killing respectively, and have been used for single bag of blood-plasma virus killing.It is professional that the Blood Transfusion Services of China nearly 1/3 has carried out blood-plasma virus killing, and clinical practice proves, the blood plasma that carries out preparing behind the blood-plasma virus killing through the methylene blue photochemical method has not been found the report of untoward reaction since clinical practice.The inactivation of virus product that existing market is used is connected to form through conduit by perforator, flow-stopping clip, methylene blue release, absorption filter, illumination bag and storage blood bag.In use, perforator is connected with the blood transfusion socket of the plasma bags for preparing, because this kind connected mode connects, perforator is an open process in the process of puncture, so this process need is operated between the sterile working.
The malicious in spite of illness inactivating device white blood cell removing plastic blood bag of disposable use of applicant's production at present goes white plastic blood bag and inactivation of virus product to combine.Blood plasma in the plasma bags is under action of gravity; The methylene blue release of flowing through gets into and shifts in the illumination bag; The illumination bag is put into the time irradiation according to the rules of blood illuminator cabinet, after irradiation finishes, and again will be through the plasma flow in the illumination bag of irradiation through the absorption filter; The methylene blue that the absorption filter adds in can adsorption filtration blood plasma under action of gravity will pass through the plasma collection of viral inactivation treatment at last and in storage blood bag, preserve.The process of whole blood preparation all is one carries out under airtight environment, can reduce the process of blood station to aseptic operation, has reduced the chance of germ contamination, the safety that can effectively improve blood products.This product needed is centrifugal together with methylene blue release and blood bag.Commercial of existing methylene blue release generally is made up of band loam cake of taking over and the lower cover that band is taken over, and adsorbate or the solid virus drugs preparation that goes out is housed in the loam cake, and covers is bonding or pass through the ultrasonic heat synthesis type by binding agent.When a whole set of blood bag was centrifugal, the seam at last lower casing ruptured easily, and when dress blood bag, in case the parts that are scattered enter into centrifugal barrel, also was easy to cause the centrifugal broken bag of blood bag.
Summary of the invention
This utility model technical problem to be solved is the deficiency that overcomes above-mentioned prior art; Provide a kind of structure reasonable; Operation, easy to use can be carried out inactivation of virus and leucocyte-removing and filter to the blood of gathering, methylene blue discharges reliable and stable; Centrifugalize safety is avoided the centrifugal broken bag new virus deactivation leukocyte depleted blood bag of blood bag.
The technical scheme that this utility model solves the problems of the technologies described above employing is: a kind of new virus deactivation leukocyte depleted blood bag; Comprise closed blood taking needle, anticoagulated whole blood bag; Anticoagulated whole blood bag bottom is connected with successively through conduit and filters dropping funnel, leucocyte-removing filter, filter back transfering bag; Filter back transfering bag is connected with blood plasma transfering bag, blood plasma transfer illumination bag and storage blood bag successively through conduit; Said blood plasma transfering bag and blood plasma shift and connect a methylene blue release on the conduit between the illumination bag, and blood plasma shifts on the conduit between illumination bag and the storage blood bag and connects an absorption filter, and said leucocyte-removing filter and absorption filter be the conduit through the parallelly connected belt switch clamp of threeway respectively; It is characterized in that: said methylene blue release is provided with a tubular shell, and the pharmaceutical carrier that contains methylene blue solution is housed in it.
The said pharmaceutical carrier of this utility model is cylindrical, and by polyester fiber or porous polypropylene material, interference fit is installed in the tubular shell.
This utility model leucocyte-removing filters and inactivation of virus combines; Whole blood collection, leucocyte-removing, separation, methylene blue add and the methylene blue filtering; All be under an airtight environment, to carry out; Can reduce to the process of aseptic operation, reduce the chance of germ contamination, can effectively improve the safety of blood products.Against existing technologies, this utility model structure is reasonable, operation, easy to use; Particularly the methylene blue release is simple in structure; The material therefor cost is low, and methylene blue discharges reliable and stable, and the seam that has solved lower casing on the existing methylene blue release is prone to disruptive problem; Centrifugalize safety has been avoided the centrifugal broken bag of blood bag.This utility model is applicable to disposable blood sampling, blood constituent separation, inactivation of virus, blood transfusion use.
Description of drawings
Below in conjunction with accompanying drawing this utility model is done further to describe.
Fig. 1 is the composition structural representation of this utility model.
Fig. 2 is the composition structural representation of this utility model methylene blue release.
1. blood taking needles among the figure, 2. conduit 3. filters dropping funnel, 4. switch clamp; 5. filter back transfering bag, 6. anticoagulated whole blood bag, 7. flow regulator, 8. leucocyte-removing filter; 9. intermediate plate clamp, 10. blood plasma transfering bag, 11. methylene blue releases, 12. blood plasma shift the illumination bag; 13. the absorption filter, 14. storage blood bags, 111. tubular shells, 112. pharmaceutical carriers.
The specific embodiment
As can be seen from Figure 1, a kind of new virus deactivation of this utility model leukocyte depleted blood bag is provided with closed blood taking needle 1, anticoagulated whole blood bag 6.Use when closed blood taking needle 1 is used for taking a blood sample, the helmet on it of fractureing just can carry out the puncture blood collecting of routine.Anticoagulated whole blood bag 6 is used for collecting whole blood.Anticoagulated whole blood bag 6 bottoms are connected with filtration dropping funnel 3, flow regulator 7, leucocyte-removing filter 8, filter back transfering bag 5 successively through conduit 2, and filter back transfering bag 5 is connected with blood plasma transfering bag 10, blood plasma transfer illumination bag 12 and storage blood bag 14 successively through conduit.Filter dropping funnel 3 and be used for grumeleuse and impurity in the filtering blood.Flow regulator 7 is used for regulating, the flow of controlled filter blood.Filter back transfering bag 5 is used for collecting filter back leucocyte-removing blood, and uses when being used for match, blood transfusion.8 pairs of whole bloods of leucocyte-removing filter or blood constituent carry out leucocyte-removing and filter.Leucocyte-removing filter 8 is through the conduit of threeway parallel connection one belt switch clamp 4.During the operation of leukocyte in the filtering blood, close switch clamp 4, the blood in the anticoagulated whole blood bag 6 through filtration dropping funnel 3, leucocyte filter 8 gets in the transfering bags 5 of filter back.Open switch clamp 4 after filtration finishes, get rid of the gas in the transfering bag 5 of filter back, after the air scavenge, close switch clamp 4 again.Heat seal sealing filter back transfering bag 5 supplies match, blood transfusion to use.
This utility model anticoagulated whole blood bag 6, filter back transfering bag 5 can add anticoagulant and the alserver's solution that meets the pharmacopeia regulation according to the rules, and have and supporting formula conduction element easy to break and the socket of blood bag simultaneously.Alserver's solution begins to be stored in the storage blood bag 14, and therefore, storage blood bag 14 also is the alserver's solution bag.
This utility model blood plasma transfering bag 10, blood plasma shift illumination bag 12 and are used for centrifugalize and filter back blood plasma deposit, transfer, illumination inactivation of virus.On the conduit between filter back transfering bag 5 and the blood plasma transfering bag 10; Blood plasma transfering bag 10 and blood plasma shift on the conduit between the illumination bag 12; Blood plasma shifts on the conduit between illumination bag 12 and the storage blood bag 14 and is separately installed with intermediate plate clamp 9; Be used for by the operating process requirement circulation of control respective liquid composition.
Said blood plasma transfering bag 10 of this utility model and blood plasma shift and connect a methylene blue release 11 on the conduit between the illumination bag 12.Blood plasma shifts on the conduit between illumination bag 12 and the storage blood bag 14 and connects an absorption filter 13, and said absorption filter 13 is the conduit through threeway parallel connection one belt switch clamp also, so as to filter finish after, get rid of the gas of storing in the blood bag 14.
The said methylene blue release 11 of this utility model is provided with a tubular shell 111, and the pharmaceutical carrier 112 that contains methylene blue solution is housed in it.As shown in Figure 2.Add the methylene blue solution that is adsorbed with doses on the pharmaceutical carrier 112.Said pharmaceutical carrier 112 is cylindrical, and by polyester fiber or porous polypropylene material, interference fit is installed in the tubular shell 111.111 liang of end connectors of said tubular shell are connected with conduit respectively, connect simple and reliable.Tubular shell 111 itself can be a section of common conduit.Such methylene blue release 11 is simple in structure, and the material therefor cost is low, has avoided occurring breaking owing to the seam of lower casing on the methylene blue release, causes the phenomenon of the centrifugal broken bag of blood bag, has improved the safety of centrifugalize.Methylene blue discharges also more reliable and more stable.
The use of this utility model is: with closed blood taking needle 1 whole blood is collected in the anticoagulated whole blood bag 6.Blood heat is reduced to 4 ℃; With 6 reversals of the natural order of things of anticoagulated whole blood bag, action of gravity is flowed through whole blood and is filtered dropping funnel 3, leucocyte-removing filter 8 begins to filter leukocyte, and the blood constituent after filter is white enters in the transfering bag 5 of filter back; White device of filter and anticoagulated whole blood bag 6 are removed in heat seal.Blood constituent in the filter back transfering bag 5 carries out centrifugalize immediately, and blood plasma is transferred in the blood plasma transfering bag 10.Then the blood plasma in the blood plasma transfering bag 10 is centrifugal again, and flow through methylene blue release 11 of supernatant gets into blood plasma and shifts in the illumination bags 12, and at this moment, blood plasma shifts in the blood plasma of illumination bag 12 and added methylene blue.Then blood plasma is shifted illumination bag 12 and put into the malicious cabinet that goes out, the time is according to the rules carried out the illumination inactivation of virus.After the illumination; Blood plasma in the blood plasma transfer illumination bag 12 is under action of gravity; Flow through and adsorb filter 13, the methylene blue that adds in the adsorption filter 13 adsorption filtration blood plasma, methylene blue that adds in the removal blood plasma and the leukocyte in the blood plasma; At last, the plasma collection that will pass through viral inactivation treatment is preserved in storage blood bag 14.
Claims (2)
1. new virus deactivation leukocyte depleted blood bag; Comprise closed blood taking needle, anticoagulated whole blood bag; Anticoagulated whole blood bag bottom is connected with successively through conduit and filters dropping funnel, leucocyte-removing filter, filter back transfering bag; Filter back transfering bag is connected with blood plasma transfering bag, blood plasma transfer illumination bag and storage blood bag successively through conduit; Said blood plasma transfering bag and blood plasma shift and connect a methylene blue release on the conduit between the illumination bag, and blood plasma shifts on the conduit between illumination bag and the storage blood bag and connects an absorption filter, and said leucocyte-removing filter and absorption filter be the conduit through the parallelly connected belt switch clamp of threeway respectively; It is characterized in that: said methylene blue release is provided with a tubular shell, and the pharmaceutical carrier that contains methylene blue solution is housed in it.
2. new virus deactivation leukocyte depleted blood bag according to claim 1, it is characterized in that: said pharmaceutical carrier is cylindrical, by polyester fiber or porous polypropylene material, interference fit is installed in the tubular shell.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012201105469U CN202490227U (en) | 2012-03-22 | 2012-03-22 | Novel viral inactivation leukocyte-reduction blood bag |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012201105469U CN202490227U (en) | 2012-03-22 | 2012-03-22 | Novel viral inactivation leukocyte-reduction blood bag |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN202490227U true CN202490227U (en) | 2012-10-17 |
Family
ID=46996473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012201105469U Expired - Lifetime CN202490227U (en) | 2012-03-22 | 2012-03-22 | Novel viral inactivation leukocyte-reduction blood bag |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN202490227U (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103861132A (en) * | 2012-12-18 | 2014-06-18 | 苏州排头兵药业科技有限公司 | Plasma and plasma product virus inactivation device |
| CN108042858A (en) * | 2017-12-29 | 2018-05-18 | 武汉佰美斯医疗科技有限公司 | A kind of blood-plasma virus killing process data recording method |
| CN108379603A (en) * | 2018-03-05 | 2018-08-10 | 田耘博 | A kind of ultrasonic wave blood-plasma virus killing method and system |
-
2012
- 2012-03-22 CN CN2012201105469U patent/CN202490227U/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103861132A (en) * | 2012-12-18 | 2014-06-18 | 苏州排头兵药业科技有限公司 | Plasma and plasma product virus inactivation device |
| CN108042858A (en) * | 2017-12-29 | 2018-05-18 | 武汉佰美斯医疗科技有限公司 | A kind of blood-plasma virus killing process data recording method |
| CN108379603A (en) * | 2018-03-05 | 2018-08-10 | 田耘博 | A kind of ultrasonic wave blood-plasma virus killing method and system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103055365B (en) | The blood processing system of autologous storage blood | |
| CN202236530U (en) | Leucocyte removal blood bag capable of inactivating viruses | |
| CN202490227U (en) | Novel viral inactivation leukocyte-reduction blood bag | |
| CN202761782U (en) | Bacteria-removing inactivation medicament and white cell filtering device | |
| CN201308491Y (en) | Removing white blood cells blood bag of red cell suspension filtering type | |
| CN103341219A (en) | Blood collection and transfusion integrated device | |
| CN202036601U (en) | Pocket type blood ingredient separator | |
| CN202740489U (en) | Blood filter and virus inactivation blood sampling union bag | |
| RU2285543C2 (en) | Device for removing gel inclusions, micro aggregate particles and leukocytes from blood products | |
| JPH03284263A (en) | Device for collecting plasma and concentrated erythrocyte | |
| CN203108265U (en) | Device for removing leukocyte in blood platelets | |
| CN2798936Y (en) | Disposable blood virus deactivation blood filtering bag | |
| CN201271255Y (en) | Blood bag with device for inactivating and filtering blood plasma virus | |
| CN1814310A (en) | Disposable viral inactivating blood transfusion filting device | |
| CN2439861Y (en) | Blood-plasma single-collecting filter-memberane separator | |
| CN102430161B (en) | Multifunctional blood collection | |
| CN2595373Y (en) | Disposable filter for virus inactivation and blood transfusion | |
| CN201409924Y (en) | Disposable soft bag leukoreduced blood collection and transfusion device | |
| CN100490909C (en) | Soft package blood component filter and its processing process | |
| CN204661734U (en) | Biotherapy closed type multifunctional unit system | |
| CN203355011U (en) | Blood collection and blood transfusion integrating device | |
| CN203017465U (en) | Autologous blood storage blood processing system | |
| CN201308490Y (en) | Blood bag system connected with various blood components filtering device | |
| CN110484502A (en) | A kind of activity leukocyte collection device and collection method | |
| RU2335302C2 (en) | Device for recovery and reinfusion of blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20121017 |